Widely used:Recently Viewed
Clear All
$2.00
$0.35
(21.21%)
As on 18-Mar-2025 14:41EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
4.01
Industry P/E
--
Debt to Equity
0.01
ROE
-1.58 %
ROCE
-141.15 %
Div. Yield
0 %
Book Value
0
EPS
-0
CFO
$-86.58 Mln
EBITDA
$-84.58 Mln
Net Profit
$-87.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| 23.08 | 30.72 | 40.85 | -5.66 | -41.13 | -31.64 | -43.93 |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| -25.95 | -64.11 | -52.71 | -27.53 | -46.06 | -82.54 | -14.80 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.62 | 200.22 | -- | -- | |
| 7.52 | 198.54 | -- | -88.96 | |
| 1.74 | 234.78 | -- | -136.88 | |
| 0.76 | 25.14 | 19.23 | -1112.14 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead... drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Address: 26 Ben Gurion Street, Ramat Gan, Israel, 5257346 Read more
Founder, Chief Scientific Officer & Executive Chairperson
Dr. Pnina Fishman Ph.D.
CEO and Chief Financial & Operating Officer
Mr. Motti Farbstein
Headquarters
Ramat Gan
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR stood at $ 10 Mln as on 31-Dec-23
The share price of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is $2.00 (NYSE) as of 18-Mar-2025 14:41 EDT. Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has given a return of -41.13% in the last 3 years.
Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has a market capitalisation of $ 10 Mln as on 17-Mar-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR and enter the required number of quantities and click on buy to purchase the shares of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Address: 26 Ben Gurion Street, Ramat Gan, Israel, 5257346
The CEO & director of Dr. Pnina Fishman Ph.D.. is Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR, and CFO & Sr. VP is Mr. Motti Farbstein.
There is no promoter pledging in Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
29
|
|
|
21
|
|
|
20
|
|
|
2
|
| Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-142.49
|
|
Operating margin(%)
|
-1102.96
|
|
Net Margin(%)
|
-1027.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR was $-3 Mln.
